Abstract

Provided is a method for predicting drug efficacy of lung cancer, including providing a biological sample of a subject with lung cancer; analyzing an expression level of Leucine Zipper Down-regulated in Cancer 1; and predicting the drug efficacy based on the expression level of the Leucine Zipper Down-regulated in Cancer 1. Also provided is kit for predicting drug efficacy of lung cancer in a subject in need thereof, including an antibody against Leucine Zipper Down-regulated in Cancer 1 or a Leucine Zipper Down-regulated in Cancer 1-specific primer. Further provided is a method for treating lung cancer, including enhancing expression of Leucine Zipper Down-regulated in Cancer 1 encoded by Ldoc1 gene in a subject in need thereof.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure provides a method for inhibiting adipocyte differentiation and/or inducing adipocyte death in a subject, comprising administrating an electrophilic (unsaturated) fatty acid (such as an electrophilic nitro-fatty acid) to a subject in need thereof.

IPC Classes  ?

• A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

The present invention provides a method for preparing an activated carbon, which includes impregnating a carbonaceous material with carbonated water; and exposing the carbonaceous material to microwave radiation to produce the activated carbon.

IPC Classes  ?

• C01B 32/318 - Preparation characterised by the starting materials
• C01B 32/336 - Preparation characterised by gaseous activating agents
• C01B 32/366 - Reactivation or regeneration by physical processes, e.g. by irradiation, by using electric current passing through carbonaceous feedstock or by using recyclable inert heating bodies

Abstract

A laser speckle contrast imaging system includes a laser light source, configured to emit a laser beam on a subject; a plurality of visible light sources, configured to respectively emit a visible light beam on the subject; an image capturing module, configured to obtain a first image corresponding to the laser beam emitting toward the subject and a plurality of second images corresponding to the plurality of visible light beams emitting toward the subject; and an image processor, coupled to the image capturing module, configured to process the first image with a laser speckle stacking algorithm to determine a variation of a cortical spreading depression (CSD) waveform according to at least a speckle pattern determined in the first image.

IPC Classes  ?

• A61B 5/026 - Measuring blood flow
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• G02B 27/48 - Laser speckle optics

Abstract

A method for establishing a disease prediction model is provided. The method includes the steps of extracting feature values for multiple microbiota features from microbiota data of each of a plurality of samples, selecting a portion of the extracted microbiota features as selected features, and training a disease prediction model. Each piece of training data used in training the disease prediction model includes (i) disease data for each of the samples and (ii) the feature values of the selected features for the sample. The microbiota features include species-level features, microbiota interaction features, and community-level features.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The invention relates to a microfluidic chip for motion-based dynamic phenotypic antibiotic drug testing. The microfluidic chip designed with 1000 observation-chambers which physically-traps ˜200 individual bacterium using oil-liquid cutting under certain operational conditions. The oil infusion provides separation of monodispersed pico-chamber volumes within 20 sec. The utility of the microfluidic chip was successfully demonstrated by multi-parametric motion-analysis of ampicillin and gentamicin treated E. coli 25922GFP™ for 21 hours of incubation at 37° C. The large-scanned images are utilized for the enumeration of viable, unculturable, filamentous and dead bacteria isolated in the device. The 2D motion-analysis are found useful for the rapid antibiotic susceptibility testing (AST) within 4 hours. The present invention can also be useful for phenotypic AST of clinical isolates and shed light on the early diagnosis and treatment of antibiotic resistant bacterial diseases in the future.

IPC Classes  ?

• C12Q 1/18 - Testing for antimicrobial activity of a material
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means

Abstract

The present invention discloses an antibody comprising an immunoglobulin Y (IgY) against the P protein of Human Norovirus (HuNoVs), which can be used for virus detection, treatment, and prevention of infection.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
• A61P 31/12 - Antivirals

Abstract

An influenza virus immunogenic composition comprises: a hemagglutinin antigen; a first adjuvant which is an aluminum salt; and a second adjuvant which is CpG oligonucleotides having a sequence of 5'-TGACTGTGAACGTTCGAGATGA-3' (SEQ ID NO: 1).

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 37/04 - Immunostimulants
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors

Abstract

The present invention uses the natural polymer alginate, as an example, to cross-link with Thioglycolic acid to form a sulfur polymer gel called Thiolated Alginate (TA). Thiolated alginate (TA) utilizes the redox reaction of the mucous membrane to the sulfur group, so that its materials can be covalently bonded by disulfide bonds, so as to prolong the residence time of the materials in the intestinal tract, at the same time, to form a thin film in the intestinal tract to reduce energy intake and achieve the effect of preventing or controlling obesity.

IPC Classes  ?

• A61L 31/04 - Macromolecular materials
• C08L 5/04 - Alginic acidDerivatives thereof

Abstract

The present disclosure provides a method for selecting a drug candidate for treating or preventing or delaying the onset or progression of an amyloidogenic disease, comprising: (a) contacting an analyte with amyloid peptide 1-42 (Aβ42) and an amphiphilic liposaccharide or a part thereof, wherein the amphiphilic liposaccharide or the part thereof is capable of forming a complex with Aβ42; and (b) determining if the analyte extends an oscillatory event of the complex; and the analyte is selected as the drug candidate.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

A method for preventing, treating or ameliorating NETosis-mediated disease in a subject, comprising administering to the subject an active agent selected from the group consisting of an adenosine receptor (AR)-specific antagonist or inhibitor, a protein arginine deiminase 4 (PAD4)-specific antagonist or inhibitor, and an elastase-specific antagonist or inhibitor.

IPC Classes  ?

• A61K 31/52 - Purines, e.g. adenine
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper

Abstract

A humanized anti-neurotensin receptor 1 (NTSR1) antibody or an antigen-binding fragment thereof. Also, a method for treating, prophylactic treating and/or preventing diseases and/or disorders caused by or related to NTSR1 activity and/or signaling, and a method or kit for detecting NTSR1 in a sample.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The present disclosure relates to a humanized anti-neurotensin receptor 1 (NTSR1) antibody or an antigen-binding fragment thereof. The present disclosure also relates to a method for treating, prophylactic treating and/or preventing diseases and/or disorders caused by or related to NTSR1 activity and/or signaling, and a method or kit for detecting NTSR'l in a sample.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

Disclosed are compounds compound of Formula (I): Disclosed are compounds compound of Formula (I): Each variable is defined herein. Also included are pharmaceutical compositions containing such a compound and a method of treating an inflammatory condition.

IPC Classes  ?

• C07D 493/04 - Ortho-condensed systems
• C07D 307/935 - Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

The present invention relates to a method for reducing localized fat deposits in a subject in need thereof in need thereof by topically treating the subject with rare-earth element doped calcium carbonate particles in combination with low-intensity ultrasound. The rare-earth element doped calcium carbonate particles have good biocompatibility and can increase reactive oxygen species (ROS) production and produce carbon dioxide (CO2) and calcium ions (Ca2+) in the region of administration under the ultrasonic irradiation. The method of the present invention is effective in inducing adipocyte necrosis, inhibiting adipogenesis, and decreasing body weight and useful for body sculpture.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 33/10 - CarbonatesBicarbonates
• A61N 7/00 - Ultrasound therapy

Abstract

A laser speckle contrast imaging system includes a laser beam, configured to emit an object; an image capturing module, configured to capture an image data of the object; and a processing unit, coupled to the laser beam and the image capturing module, configured to generate a first image and a second image corresponding to the laser beam according to the image data, and to perform an auto-tracking function for an interest of region (ROI) of the second image and update the second image according to an auto-tracking result of the ROI.

IPC Classes  ?

• G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
• H04N 23/21 - Cameras or camera modules comprising electronic image sensorsControl thereof for generating image signals from infrared radiation only from near infrared [NIR] radiation
• H04N 23/56 - Cameras or camera modules comprising electronic image sensorsControl thereof provided with illuminating means

Abstract

A method for covalently joining linear RNA molecules end-to-end to extend their functionality. A cis-acting ligase ribozyme is used to generate circular RNA in vitro for ectopic protein expression. RNA circularization was confirmed by masking the 5' phosphate group, resisting exonuclease RNase R digestion, and sequencing the RT-PCR products of the joined region. Furthermore, one internal ribosome entry site rendered oRNA translation competent, but two IRES in cis, not tans, hampered the translation and an oRNA expressing ribonuclease Cas13 showed excellent potential against the corresponding RNA virus. A method for using oRNA is also provided.

IPC Classes  ?

• C12N 15/30 - Genes encoding protozoal proteins, e.g. from Plasmodium, Trypanosoma, Eimeria
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

A pH-responsive hydrogel, which is synthesized by using mixed pectin and sucralfate treated with a small amount of acid to form a pH-responsive hydrogel. The pH-responsive hydrogel can form a temporary coating on the surface of the gastrointestinal tract to reduce excessive nutrient absorption, and exhibits excellent barrier properties and mucosal adhesion effects, which are useful for reducing blood sugar rise and weight gain, the liver fat accumulation, body fat accumulation and blood low-density lipoprotein that have a significant effect. In addition, the technical principles disclosed in the pH-responsive hydrogel should be applied to other polymer materials to manufacture different pH-responsive hydrogels.

IPC Classes  ?

• A61K 31/732 - Pectin
• A61K 9/06 - OintmentsBases therefor
• A61K 31/737 - Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

Disclosed is an adapted Madin-Darby canine kidney cell line capable of suspension culture in the absence of serum, and a chemically-defined medium for culture of the adapted MDCK cell line. Further disclosed are culture methods for growing the adapted MDCK cell line and methods for producing a vaccine from the adapted MDCK cell line grown in the chemically-defined medium.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/12 - Viral antigens
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Provided is a pharmaceutical composition including an active pharmaceutical ingredient, a toll-like receptor (TLR) agonist, a stimulator of interferon genes (STING) agonist, and a pharmaceutically acceptable carrier. Also provided are a method for inducing immune response and a method for treating or preventing cancer or an infectious disease, including administering an effective amount of the pharmaceutical composition to a subject in need thereof.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 35/00 - Antineoplastic agents

Abstract

14166, and Het are defined herein. Also disclosed are a pharmaceutical composition containing such a compound and methods of using the compound to treating disorders associated with TAM.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• C07D 487/04 - Ortho-condensed systems
• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Abstract

An electronic device and a method for diagnosing heart state based on electrocardiogram (ECG) are provided. An ECG file is obtained, and the ECG file is in a first file format and includes a plurality of potential traces of a plurality of leads. The ECG file is converted to a second file format to obtain electrocardiogram data corresponding to multiple leads. Each potential trace relative to time in the ECG file is converted to the ECG data of each lead. Integrated ECG data associated with the leads is generated based on the ECG data of the plurality of leads through the zero-padding operation and the stacking operation. A diagnostic result of heart status is generated based on the integrated ECG data and a deep learning model.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Provided is a pharmaceutical combination for preventing or treating a neurodegenerative disease. The pharmaceutical combination includes a first agent being an insulin sensitizer and a second agent being a lipid metabolism modulator. Also provided is a method for preventing or treating a neurodegenerative disease in a subject in need thereof by administering the first agent and the second agent to the subject, thereby reducing the visceral adiposity and the accumulation of amyloid β peptides in the subject.

IPC Classes  ?

• A61K 31/426 - 1,3-Thiazoles
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/425 - Thiazoles
• A61K 31/33 - Heterocyclic compounds

Abstract

Methods of treating a disease caused by a positive strand RNA virus. The methods include administering to a subject in need thereof an effective amount of a compound of Formula I.

IPC Classes  ?

• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 31/14 - Antivirals for RNA viruses
• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine

Abstract

The present disclosure relates to a vaccine composition, comprising a recombinant lipidated FLIPr (rLF), and the use thereof in enhancing humoral and cellular immune responses. The recombinant lipidated FLIPr of present invention may be used as a vaccine candidate that can induce anti-FLIPr responses to overcome FLIPr-mediated inhibition. And unexpectedly, the recombinant lipidated FLIPr may be used as an adjuvant that can enhance other vaccine immune responses, especially in subunit vaccines and inactivated virus vaccines.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/12 - Viral antigens
• A61K 39/09 - Streptococcus
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/04 - Antibacterial agents
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

Provided is a method for preventing or treating urological chronic pelvic pain syndrome (UCPPS) in a subject that includes administering an effective amount of cerium oxide nanoparticles (CeNPs) to the subject. Also provided is a method for preventing or treating an UCPPS in a subject that includes administering to the subject a pharmaceutical composition comprising an effective amount of the CeNPs and a pharmaceutically acceptable carrier thereof.

IPC Classes  ?

• A61K 33/24 - Heavy metalsCompounds thereof
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61K 9/51 - Nanocapsules

Abstract

Disclosed is a pharmaceutical nanoparticle containing a core and a shell coating the core. The core contains (3-{4-[2-({4-[3-(3-cyclohexylamino-propylamino)-propyl]-oxazol-2-ylmethyl}-amino)-6-methyl-pyrimidin-4-ylamino]-piperidin-1-yl}-3-oxo-propylamino)-acetic acid or a salt thereof, 1,2-dioleoyl-sn-glycero-3-phosphate, and an anionic polymer. The shell contains a lipid. Also disclosed is a method for preparing such as pharmaceutical nanoparticle. Further provided are a liposome containing a lipid bilayer enclosing an aqueous core and its preparation method.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 31/05 - Phenols

Abstract

Disclosed is a pharmaceutical nanoparticle containing a core and a shell coating the core. The core contains (3-{4-[2-({4-[3-(3-cyclohexylamino- propylamino)-propyl]-oxazol-2-ylmethyl}-amino)-6-methyl-pyrimidin-4-ylamino]- piperidin-1-yl}-3-oxo-propylamino)-acetic acid or a salt thereof, 1,2-dioleoyl-sn- glycero-3-phosphate, and an anionic polymer. The shell contains a lipid. Also disclosed is a method for preparing such as pharmaceutical nanoparticle. Further provided are a liposome containing a lipid bilayer enclosing an aqueous core and its preparation method.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/42 - Oxazoles
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/33 - Heterocyclic compounds

Abstract

A composition is provided, wherein the composition includes a subunit vaccine including a first amount of a subunit, and a nucleic acid vaccine including a second amount of a vector.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 47/02 - Inorganic compounds
• A61P 31/12 - Antivirals
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

A nucleic acid-lipid nanoparticle is provided, which comprises: a nucleic acid molecule and a lipid mixture. The lipid mixture comprises: an ionizable amino lipid present in an amount of 20 mol % to 60 mol %; a phospholipid present in an amount of 5 mol % to 20 mol %; cholesterol present in an amount of 25 mol % to 60 mol %; and a PEGylated lipid present in an amount of 0.2 mol % to 6 mol %. In addition, methods using the aforesaid nucleic acid-lipid nanoparticle are also provided.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• C12N 15/50 - Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Abstract

Disclosed are compounds of formula (I) as follows: 1, W, and Het is defined herein. Also provides are a method of inhibiting prostaglandin reductase 2 (“PTGR2”) using such a compound and a pharmaceutical composition containing same.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07D 239/56 - One oxygen atom and one sulfur atom
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A construction method of ribosomal RNA database is provided, including the following steps: selecting a source of nucleic acid sequence database; performing normalization and homogenization on species classification rules; using AI technology for normalized classification and correction; selecting the kingdom to which the sequence species belongs; filtering out redundant sequences and sequences with inconsistent lengths; setting a threshold for unknown bases other than A, T, C or G, and excluding unknown bases that exceed the threshold; and excluding sequences with insufficient classification information.

IPC Classes  ?

• G16B 40/20 - Supervised data analysis
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 50/30 - Data warehousingComputing architectures

Abstract

The disclosure provides methods of using biomarkers to predict risk or likelihood and/or prognosis of and/or detect or diagnose substance use disorders or infections and/or monitor progress of substance use disorders and infections.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/94 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving narcotics
• G01N 33/98 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving alcohol, e.g. ethanol in breath
• G01N 33/576 - ImmunoassayBiospecific binding assayMaterials therefor for hepatitis

Abstract

The invention relates to a reconstructed human skin equivalent and a method for producing the same, comprising: culturing a population of fibroblast and keratinocyte in a first medium, mixing the fibroblasts with a hydrogel to obtain a hydrogel-cell mixture; culturing the hydrogel-cell mixture with the first medium to obtain a dermal layer; seeding the keratinocyte onto the dermal layer; adjusting the level of the second medium and continuous culture to obtain the recombinant skin equivalent unit.

IPC Classes  ?

• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages

Abstract

The present invention discloses a process for preparing compounds of Formula (I), particularly, a process manufacturing thereof on a multikilogram scale: 2, and n are defined herein.

IPC Classes  ?

• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A feature selection method is provided, including: inputting a plurality of pieces of training data into a plurality of training models to perform selection in a plurality of features through each training model for obtaining multiple feature pools; sorting the features based on the number of times each feature is selected by the feature pools to obtain a feature ranking; and extracting a plurality of designated features from the features based on the feature ranking.

IPC Classes  ?

• G06N 20/00 - Machine learning

Abstract

A laser speckle contrast imaging system includes a laser light source, configured to emit a laser beam on a subject; a plurality of visible light sources, configured to respectively emit a visible light beam on the subject; an image capturing module, configured to obtain a first image corresponding to the laser beam emitting toward the subject and a plurality of second images corresponding to the plurality of visible light beams emitting toward the subject; and an image processor, coupled to the image capturing module, configured to process the first image with a laser speckle stacking algorithm to determine a variation of a cortical spreading depression (CSD) waveform according to at least a speckle pattern determined in the first image.

IPC Classes  ?

• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/0265 - Measuring blood flow using electromagnetic means, e.g. electromagnetic flow meter
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment

Abstract

The present disclosure relates to a scaffold with staircase microstructure for cell or tissue culture, comprising multiple layers. Each layer defines a plurality of through holes, and the through holes of each layer is in communication with a corresponding through holes of an adjacent layer. A method for culturing cell and tissue regeneration is also provided.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

An isolated antibody, comprising: a heavy chain variable domain (VH) that is at least 75% identical to the amino acid sequence of SEQ ID NO: 1; and a light chain variable domain (VL) that is at least 75% identical to the amino acid sequence of SEQ ID NO: 2; wherein the antibody binds specifically to human neurotensin receptor 1 (hNTSR1).

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

A system and method for controlling an elevator equipped with an automated external defibrillator (AED). The method includes determination of an elevator controlling device in response to a signal triggered by an AED calling device under the condition that whether the elevator is in motion. When the elevator is not in motion, the elevator controlling device issues a direct arrival instruction and sends the elevator directly to the floor where the AED calling signal is triggered. When the elevator is in motion, the elevator controlling device issues a priority arrival instruction and sends the elevator to a default floor and then to the floor where the AED calling signal is triggered. After the AED is taken out, the elevator resumes its original operation.

IPC Classes  ?

• B66B 1/24 - Control systems with regulation, i.e. with retroactive action, for influencing travelling speed, acceleration, or deceleration
• B66B 1/46 - Adaptations of switches or switchgear
• B66B 11/02 - Cages
• A61N 1/39 - Heart defibrillators

Abstract

The present disclosure relates to a method of ending a double-stranded DNA with at least one stem-loop and a kit thereof. It comprises treating a linear double-stranded DNA with at least one primer, a DNA exonuclease, a DNA polymerase, and a DNA ligase. This method is a one-step reaction for obtaining a DNA with at least one stem-loop without using PCR or modification of ends of the linear double-stranded DNA template.

IPC Classes  ?

• C12Q 1/6855 - Ligating adaptors
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

Abstract

Disclosed is an isolated antibody comprises: novel complementarity determining regions capable of specifically binding to the HSP90α epitope containing two EDK sites in the amino acid 235 to 244 and amino acid 251 to 260 regions, respectively. Also disclosed are nucleic acid molecules corresponding to the aforesaid antibody, a pharmaceutical composition comprising the aforesaid antibody or the corresponding nucleic acid molecules, and the methods for treating and monitoring a cancer using the aforesaid antibody.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The present invention relates to a method for body weight control in a subject in need thereof, comprising administering an effective amount of a thiolated chitosan to the subject. In particular, the thiolated chitosan of the present invention comprises a plurality of thiol groups covalently bonded to a chitosan moiety thereof. The thiolated chitosan of the present invention can be orally administered, which is effective in slowing down body weight gain and has good biocompatibility.

IPC Classes  ?

• A61K 31/722 - ChitinChitosan
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Pyrimidine compounds of Formula (I). Assignments to the variables in the formula are set forth herein. Also disclosed is a method of treating cancer with one of the pyrimidine compounds. Pyrimidine compounds of Formula (I). Assignments to the variables in the formula are set forth herein. Also disclosed is a method of treating cancer with one of the pyrimidine compounds.

IPC Classes  ?

• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61P 35/00 - Antineoplastic agents
• A61P 11/00 - Drugs for disorders of the respiratory system
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 487/08 - Bridged systems
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Disclosed are methods for treatments of conditions involving CD47 upregulation using a compound of formula (I): Disclosed are methods for treatments of conditions involving CD47 upregulation using a compound of formula (I): Disclosed are methods for treatments of conditions involving CD47 upregulation using a compound of formula (I): Variables R1-R9, X, and Het are defined therein. Also disclosed are methods for increasing phagocytosis of a cell using such a compound and pharmaceutical compositions each containing the compound and an anti-cancer agent.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/4245 - Oxadiazoles
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61P 35/00 - Antineoplastic agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A method of treating a Cisd2 insufficiency-associated disorder. The method includes administering to a subject in need a compound of formula (I). Also disclosed is a method of increasing Cisd2 gene expression.

IPC Classes  ?

• C07D 333/36 - Nitrogen atoms
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

Disclosed are methods for treatments of conditions involving CD47 upregulation using a compound of formula (I):(see formula I)Variables R1-R9, X, and Het are defined therein. Also disclosed are methods for increasing phagocytosis of a cell using such a compound and pharmaceutical compositions each containing the compound and an anti-cancer agent.

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/4245 - Oxadiazoles
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

Pyrimidine compounds of formula (I) shown herein. Also disclosed are pharmaceutical compositions containing one of the pyrimidine compounds and methods of using the pyrimidine compounds to treat or prevent chemotherapy-induced peripheral neuropathy.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61P 23/00 - Anaesthetics
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

The present invention discloses a combinational therapy for enhancing efficacy of immune checkpoint blockade for tumors with immune suppressive microenvironment. More specifically, this combination therapy involves the treatment of cancer through immune checkpoint inhibitors and CpG-oligodeoxynucleotides.

IPC Classes  ?

• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links

Abstract

A method of treating a Cisd2 insufficiency-associated disorder. The method includes administering to a subject in need a compound of formula (I). Also disclosed is a method of increasing Cisd2 gene expression.

IPC Classes  ?

• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• C07D 333/36 - Nitrogen atoms
• C07D 333/38 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/14 - Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Abstract

A wearable ultrasonic therapeutic device controlled by a mobile electronic device is provided, which includes a mobile device, at least one ultrasonic probe module and a strap. The mobile device has a mobile device control interface for setting ultrasonic parameters and displaying an echo wave through a specific software interface of the mobile device. The ultrasonic probe module includes at least one ultrasonic transducer and a control circuit corresponding thereto. The ultrasonic transducer generates and receives an ultrasonic wave. The control circuit has the functions of generating/receiving signals, phase regulation, power amplification and matching. One end of the ultrasonic probe module is electrically connected to the mobile device and the other end of the ultrasonic probe module is connected to the strap.

IPC Classes  ?

• A61N 7/00 - Ultrasound therapy
• A61B 8/14 - Echo-tomography
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves

Abstract

A system for assessing risks of T2DM complications includes: a data acquisition module obtaining and inputting assessment parameters of a patient with T2DM into a risk assessment module; and the risk assessment module inputting the assessment parameters into a number of risk equations and using it to calculate risk values of the complication occurring after a period of time. The risk equation for all diabetic complications (i,j) is: A system for assessing risks of T2DM complications includes: a data acquisition module obtaining and inputting assessment parameters of a patient with T2DM into a risk assessment module; and the risk assessment module inputting the assessment parameters into a number of risk equations and using it to calculate risk values of the complication occurring after a period of time. The risk equation for all diabetic complications (i,j) is: ra(t,i,j)=1−exp{[H(t0)−H(t1)]Ca(t,i,j)} A system for assessing risks of T2DM complications includes: a data acquisition module obtaining and inputting assessment parameters of a patient with T2DM into a risk assessment module; and the risk assessment module inputting the assessment parameters into a number of risk equations and using it to calculate risk values of the complication occurring after a period of time. The risk equation for all diabetic complications (i,j) is: ra(t,i,j)=1−exp{[H(t0)−H(t1)]Ca(t,i,j)} ra(t, i, j) is the risk value for the patient to develop the complication j from the current disease i at age t. t0 is an age of one patient at a state of the disease i. t1 is an age of the patient after the period of time. t is an age between t0 and t1. H(t0) and H(t1) are hazards of the complication occurring at the age t0 and the age t1, respectively. Ca(t, i, j) is a Cox proportional hazards regression expression, and is represented by: A system for assessing risks of T2DM complications includes: a data acquisition module obtaining and inputting assessment parameters of a patient with T2DM into a risk assessment module; and the risk assessment module inputting the assessment parameters into a number of risk equations and using it to calculate risk values of the complication occurring after a period of time. The risk equation for all diabetic complications (i,j) is: ra(t,i,j)=1−exp{[H(t0)−H(t1)]Ca(t,i,j)} ra(t, i, j) is the risk value for the patient to develop the complication j from the current disease i at age t. t0 is an age of one patient at a state of the disease i. t1 is an age of the patient after the period of time. t is an age between t0 and t1. H(t0) and H(t1) are hazards of the complication occurring at the age t0 and the age t1, respectively. Ca(t, i, j) is a Cox proportional hazards regression expression, and is represented by: Ca(t,i,j)=exp(Ra(t,i,j)) A system for assessing risks of T2DM complications includes: a data acquisition module obtaining and inputting assessment parameters of a patient with T2DM into a risk assessment module; and the risk assessment module inputting the assessment parameters into a number of risk equations and using it to calculate risk values of the complication occurring after a period of time. The risk equation for all diabetic complications (i,j) is: ra(t,i,j)=1−exp{[H(t0)−H(t1)]Ca(t,i,j)} ra(t, i, j) is the risk value for the patient to develop the complication j from the current disease i at age t. t0 is an age of one patient at a state of the disease i. t1 is an age of the patient after the period of time. t is an age between t0 and t1. H(t0) and H(t1) are hazards of the complication occurring at the age t0 and the age t1, respectively. Ca(t, i, j) is a Cox proportional hazards regression expression, and is represented by: Ca(t,i,j)=exp(Ra(t,i,j)) Ra(t, i, j) is an influence degree of risk factors X on the complication j.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records

Abstract

Pyrimidine compounds of formula (I) shown herein. Also disclosed are pharmaceutical compositions containing one of the pyrimidine compounds and methods of using the pyrimidine compounds to treat or prevent chemotherapy- induced peripheral neuropathy.

IPC Classes  ?

• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Pyrimidine compounds of formula (I) shown herein. Also disclosed are pharmaceutical compositions containing one of the pyrimidine compounds and methods of using the pyrimidine compounds to treat or prevent chemotherapy- induced peripheral neuropathy.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

Isoindoline compounds and their pharmaceutical compositions. Also provided are methods of treating a Cisd2-insufficiency associated disorder and protecting against doxorubicin-induced cardiotoxicity.

IPC Classes  ?

• C07D 209/44 - Iso-indolesHydrogenated iso-indoles
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 495/04 - Ortho-condensed systems

Abstract

The invention utilizes virtual screening strategy to seek for current market drugs as anti-schizophrenia therapy drug repurposing. Drug repurposing strategy finds new uses other than the original medical indications of existing drugs. Finding new indications for such drugs will benefit patients who are in needs for a potential new therapy sooner since known drugs are usually with acceptable safety and pharmacokinetic profiles. In this study, repurposing marketed drugs for DAAO inhibitor as new schizophrenia therapy was performed with virtual screening on marketed drugs and its metabolites. The identified and available drugs and compounds were further confirmed with in vitro DAAO enzymatic inhibitory assay.

IPC Classes  ?

• C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase
• G16C 20/60 - In silico combinatorial chemistry
• G16C 20/64 - Screening of libraries
• G16B 35/00 - ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

The present invention discloses that cancer cells secrete succinate into extracellular milieu, which increases macrophage migration and mediates TAM polarization. Furthermore, succinate induces cancer cell EMT, enhances cancer cell migration, and promotes cancer metastasis in murine models. It is indicated in the present invention that serum succinate concentration is elevated in patients with lung cancer when compared to healthy subjects. It implies that during cancer development and progression, cancer cells release a large quantity of succinate into the circulation. As shown in the present invention, serum succinate has a high discriminatory power, it represents a new class of circulating oncometabolite with potential value for predicting NSCLC. Furthermore, as elevation of succinate level in LLC tumor model is accompanied by increased TAMs in the subcutaneous tumors and enhanced cancer metastasis, serum succinate may be a useful therapeutic biomarker for NSCLC treatment. The present invention also provides an anti-succinate antibody that can serve as a cancer therapeutic agent.

IPC Classes  ?

• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61P 35/00 - Antineoplastic agents

Abstract

Isoindoline compounds and their pharmaceutical compositions. Also provided are methods of treating a Cisd2-insufficiency associated disorder and protecting against doxorubicin-induced cardiotoxicity.

IPC Classes  ?

• A61K 31/4035 - Isoindoles, e.g. phthalimide
• A61P 3/00 - Drugs for disorders of the metabolism
• C07D 209/48 - Iso-indolesHydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide

Abstract

The disclosure provides a therapeutic method for preventing, ameliorating and/or treating Alzheimer's disease in a subject in need of such treatment. The therapeutic method comprises administrating to said subject a pharmaceutical combination comprising an effective amount of curcumin analog, TML-6 and an effective amount of an anti-A beta (Aβ) antibody.

IPC Classes  ?

• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

A magnetic cell biocarrier combined with a powerless bioreactor system comprising a biocarrier, a powerless bioreactor, and a magnetic field device. The biocarrier can detach the cells through temperature regulation and can be adsorbed by the magnetic field device to stabilize at the bottom of the gooseneck cell culture tank; the powerless bioreactor comprises a microinfusion element, a culture fluid collection element, and a gooseneck cell culture tank; the internal space of the gooseneck cell culture tank is interconnected with the microinfusion element and the culture fluid collection element, the microinfusion element slowly injects fresh culture medium When the culture medium in the gooseneck cell culture tank is above an overflow position, the cell metabolites can be automatically discharged to the culture fluid collection element by the interconnected vessels to reduce the risk of cell contamination.

IPC Classes  ?

• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12N 1/04 - Preserving or maintaining viable microorganisms
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood

Abstract

The present invention provides novel substituted benzimidazole derivatives used as DAAO inhibitors and for treatment and/or prevention of neurological disorders.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

The present invention provides novel substituted benzimidazole derivatives used as DAAO inhibitors and for treatment and/or prevention of neurological disorders.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

A focused ultrasound device and method for dermatological treatment. The focused ultrasound device includes a focused ultrasound applicator, an automatic motion mechanism, a driver, a computer, a software operation interface. In addition, the focused ultrasound method for dermatological treatment utilizes the same focused ultrasound applicator, to achieve coaxial deep layer and shallow layer ablation treatment of the skin.

IPC Classes  ?

• A61N 7/02 - Localised ultrasound hyperthermia
• B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction

Abstract

Heterocyclic compounds of formula I shown below and pharmaceutical compositions containing one of such compounds: Also disclosed is a method of treating a condition modulated by the colony-stimulating factor-1 receptor with one of the heterocyclic compounds. Heterocyclic compounds of formula I shown below and pharmaceutical compositions containing one of such compounds: Also disclosed is a method of treating a condition modulated by the colony-stimulating factor-1 receptor with one of the heterocyclic compounds.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 239/88 - Oxygen atoms

Abstract

An electronic device and a method for screening features for predicting a physiological state are provided. The method includes: obtaining multiple physiological data corresponding to multiple features; generating multiple first subsets of the multiple features according to the multiple physiological data based on a first model, wherein the multiple first subsets respectively correspond to the multiple physiological data; selecting a first feature from the multiple features according to the multiple first subsets, calculating a first relation index of the first feature and a second feature corresponding to the multiple features, and selecting the second feature as an accompanied feature of the first feature according to the first relation index; and outputting the first feature and the accompanied feature.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06K 9/62 - Methods or arrangements for recognition using electronic means

Abstract

An electronic device and a method for predicting a blockage of a coronary artery are provided. The method includes: obtaining multiple pieces of electrocardiogram (ECG) data respectively corresponding to a coronary artery set; generating multiple first probabilities corresponding to the multiple pieces of electrocardiogram data respectively according to the multiple pieces of electrocardiogram data and a first phase model, generating a first determined result according to the multiple first probabilities, and selecting a first data subset corresponding to a first probability subset from the multiple pieces of electrocardiogram data in response to each one in the first data subset of the multiple first probabilities being greater than a first threshold; generating multiple second probabilities corresponding to the first data subset according to the first data subset and a second phase model, and generating a second determined result according to the multiple second probabilities.

IPC Classes  ?

• A61B 5/355 - Detecting T-waves
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/341 - Vectorcardiography [VCG]
• A61B 5/352 - Detecting R peaks, e.g. for synchronising diagnostic apparatusEstimating R-R interval
• A61B 5/353 - Detecting P-waves

Abstract

An electronic device and a method for selecting a feature of an electrocardiogram (ECG) are provided. The method includes: obtaining the ECG; performing a first pre-processing on the ECG to generate a first ECG; marking multiple extreme points corresponding to at least one type of wave on the first ECG; calculating a first feature value corresponding to a first feature according to the multiple extreme points of the at least one type of wave, generating a first performance index corresponding to a machine learning model according to the first feature value, and determining whether to select the first feature according to the first performance index; and outputting the first feature in response to selecting the first feature.

IPC Classes  ?

• A61B 5/352 - Detecting R peaks, e.g. for synchronising diagnostic apparatusEstimating R-R interval
• A61B 5/353 - Detecting P-waves
• A61B 5/36 - Detecting PQ interval, PR interval or QT interval
• G06N 20/00 - Machine learning
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS

Abstract

The present invention relates to a cell line having an increased ability to produce virus and a method for preparing thereof, and more particularly, to a cell line that has an increased ability to produce virus, due to the overexpression of a CCCH-type zinc finger protein and to a production method thereof. According to the present invention, when the engineered cell line is used as a virus-producing cell line, the production yield of virus can be increased. In addition, the engineered cell line can be used for the production and research of vaccines for preventing and treating viral diseases.

IPC Classes  ?

• A61P 31/14 - Antivirals for RNA viruses
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 7/04 - Inactivation or attenuationProducing viral sub-units
• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

Provided herein are compounds of Formula (I). The compounds described herein are useful in treating a disease associated with the expression of endogenous embryonic/fetal globin (e.g., γ globin) in erythrocytes (e.g., treating β-thalassemia and/or sickle cell disease through at least the induction of the globin gene expression in erythrocytes), and/or anemia (β-thalassemia and/or sickle cell anemia). The compounds described herein are useful in treating, delaying, and/or preventing the adverse effects of β-thalassemia and/or sickle cell disease, inducing γ globin production, and/or inducing the expression of embryonic/fetal globin genes in a subject, cell, tissue, or biological sample. Also provided in the present disclosure are pharmaceutical compositions, kits, and methods of using the compounds for inducing γ globin production described herein and for treating any of the target diseases described herein.

IPC Classes  ?

• A61K 31/52 - Purines, e.g. adenine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 7/06 - Antianaemics
• C07D 473/16 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
• C07D 473/18 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Abstract

The present disclosure relates to a method for treating or preventing or delaying the onset or progression of an amyloidogenic disease in a subject in need, comprising administering a pharmaceutical composition comprising a therapeutically effective amount of amphiphilic liposaccharide to the subject. The present disclosure also relates to a method for selecting an agent for treating or preventing or delaying the onset or progression of an amyloidogenic disease and a novel liposaccharide.

IPC Classes  ?

• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Abstract

This invention provides a high-efficient single-cell collection method using a specially designed collection well and collection pipet tip for particle/cell collection from the collection well. The structures of the collection well and pipet tip eliminate fluidic dead volume in the collection, resulting in all (or most) of the particles/cells can be brought into the collection pipette tip with the flow. The advantages of this invention in cell manipulation include high cell collection efficiency, low cell damage and easy operation procedure.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• B01L 3/02 - BurettesPipettes
• C12N 1/02 - Separating microorganisms from their culture media

Abstract

Thiazole compounds of Formula (I) shown below and pharmaceutical compositions containing one of such compounds: 2 are defined in the specification. Also disclosed are methods of inhibiting a tyrosine kinase and treating cancer associated with a tyrosine kinase with one of the thiazole compounds.

IPC Classes  ?

• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The present invention relates to a novel device can be used to provide electrical transfer source, particularly to an electrical device provided square wave electric pulse that enhance nucleic acid deliver into cells by electric probe.

IPC Classes  ?

• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
• A61N 1/32 - Applying electric currents by contact electrodes alternating or intermittent currents

Abstract

Methods of treating a disease caused by a positive strand RNA virus. The methods include administering to a subject in need thereof an effective amount of a compound of Formula I or Formula II.

IPC Classes  ?

• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Compounds of Formula (I) shown below and a pharmaceutical composition containing one of the compounds. Each of the variables is defined herein. Also disclosed is a method of treating a condition associated with uncontrolled cell growth with a compound of Formula (I).

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 35/00 - Antineoplastic agents
• C07D 498/14 - Ortho-condensed systems

Abstract

Compounds of Formula (I) shown below and a pharmaceutical composition containing one of the compounds: Each of the variables is defined herein. Also disclosed is a method of treating a condition associated with uncontrolled cell growth with a compound of Formula (I).

IPC Classes  ?

• C07D 493/04 - Ortho-condensed systems
• C07D 498/14 - Ortho-condensed systems
• C07D 498/18 - Bridged systems
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61P 35/00 - Antineoplastic agents

Abstract

Compounds of Formula (I) shown below and a pharmaceutical composition containing one of the compounds. Each of the variables is defined herein. Also disclosed is a method of treating a condition associated with uncontrolled cell growth with a compound of Formula (I).

IPC Classes  ?

• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

An isolated antibody, comprising: a heavy chain variable domain (VH) that is at least 75% identical to the amino acid sequence of SEQ ID NO: 1; and a light chain variable domain (VL) that is at least 75% identical to the amino acid sequence of SEQ ID NO: 2; wherein the antibody binds specifically to human neurotensin receptor 1 (hNTSR1).

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 19/00 - Hybrid peptides
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present invention relates to a new type of metabolizable flower-like gold nanodandelion (GND), which possesses features: (1) large scale green synthesis with high monodispersity and a circa 100% yield; (2) cellular/physiological degradability; (3) precision control of the shape, petal number and size; (4) highly efficient radiotheranostics encompassing better enhanced CT contrast and pronounced x-ray induced ROS generation than conventional spherical AuNP.

IPC Classes  ?

• B22F 9/24 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
• A61K 9/14 - Particulate form, e.g. powders
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• B22F 1/054 - Nanosized particles
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• B82Y 40/00 - Manufacture or treatment of nanostructures

Abstract

HLL) that is at least 75% identical to the amino acid sequence of SEQ ID NO: 2; wherein the antibody binds specifically to human neurotensin receptor 1 (hNTSR1).

IPC Classes  ?

• A01N 43/64 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/71 -

Abstract

The present disclosure relates to a scaffold with staircase microstructure for cell or tissue culture, comprising multiple layers. Each layer defines a plurality of through holes, and the through holes of each layer is in communication with a corresponding through holes of an adjacent layer. A method for culturing cell and tissue regeneration is also provided.

IPC Classes  ?

• A61F 2/02 - Prostheses implantable into the body
• A61K 9/70 - Web, sheet or filament bases
• A61L 27/56 - Porous or cellular materials
• A61L 27/40 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• B32B 37/02 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by a sequence of laminating steps, e.g. by adding new layers at consecutive laminating stations
• B32B 3/26 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a particular shape of the outline of the cross-section of a continuous layerLayered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a layer with cavities or internal voids

Abstract

The disclosure provides methods of using biomarkers to predict risk or likelihood and/or prognosis of and/or detect or diagnose substance use disorders or infections and/or monitor progress of substance use disorders and infections.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Pyrimidine compounds of Formula (I). Assignments to the variables in the formula are set forth herein. Also disclosed is a method of treating cancer with one of the pyrimidine compounds.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61P 35/00 - Antineoplastic agents

Abstract

Pyrimidine compounds of Formula (I). Assignments to the variables in the formula are set forth herein. Also disclosed is a method of treating cancer with one of the pyrimidine compounds.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

The present invention provides a method for diagnosing asthma by using a panel of internal lipid species, including LPE 22:6, LPE 20:4, SM 16:0, PE 16:0/22:6, PE 18:0/22:6, PE 18:0/20:4 PE 18:0/18:2, and phosphatidylcholine (PC) 18:0/18:2, comprising comparing a cutoff ratio value of the panel of internal lipid species with internal lipid species ratio value for diagnosing. The present invention also provides a method for treating asthma, comprising administrating a therapeutically effective amount of a LEP 22:6 inhibitory regulator, bovine serum albumin or human serum albumin to a subject in need thereof.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol
• C07F 9/10 - Phosphatides, e.g. lecithin
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention is a method for calculating activity duration comprises collecting user data, dividing the user data into in-range and out-range node, setting the in-range node as activity start node or activity end node, setting one of the activity start/end node as period start/end node, and let the period time differential between the period start node and period end node as activity duration. A method for calculating activity efficiency comprises collecting the usage data of the mobile device, label the usage data based on the activity duration, set the labeled usage data as the dataset, and train a neural network with the dataset, wherein the trained neural network generates a feature based on the usage data, and calculate the efficiency based on the feature. The present invention greatly improves efficiency for labor inspection, and helps people with erratic work schedules to have better benefits.

IPC Classes  ?

• G06Q 10/06 - Resources, workflows, human or project managementEnterprise or organisation planningEnterprise or organisation modelling
• H04L 29/08 - Transmission control procedure, e.g. data link level control procedure
• G01S 19/01 - Satellite radio beacon positioning systems transmitting time-stamped messages, e.g. GPS [Global Positioning System], GLONASS [Global Orbiting Navigation Satellite System] or GALILEO

Abstract

Isolated antibodies that bind specifically to R-spondin 3 (RSPO3) are described. Also described herein are compositions containing the antibodies and methods of using the antibodies to treat cancer and detect RSPO3.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61P 35/00 - Antineoplastic agents
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention discloses that cancer cells secrete succinate into extracellular milieu, which increases macrophage migration and mediates TAM polarization. Furthermore, succinate induces cancer cell EMT, enhances cancer cell migration, and promotes cancer metastasis in murine models. It is indicated in the present invention that serum succinate concentration is elevated in patients with lung cancer when compared to healthy subjects. It implies that during cancer development and progression, cancer cells release a large quantity of succinate into the circulation. As shown in the present invention, serum succinate has a high discriminatory power, it represents a new class of circulating oncometabolite with potential value for predicting NSCLC. Furthermore, as elevation of succinate level in LLC tumor model is accompanied by increased TAMs in the subcutaneous tumors and enhanced cancer metastasis, serum succinate may be a useful therapeutic biomarker for NSCLC treatment. The present invention also provides an anti-succinate antibody that can serve as a cancer therapeutic agent.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

The present invention discloses that cancer cells secrete succinate into extracellular milieu, which increases macrophage migration and mediates TAM polarization. Furthermore, succinate induces cancer cell EMT, enhances cancer cell migration, and promotes cancer metastasis in murine models. It is indicated in the present invention that serum succinate concentration is elevated in patients with lung cancer when compared to healthy subjects. It implies that during cancer development and progression, cancer cells release a large quantity of succinate into the circulation. As shown in the present invention, serum succinate has a high discriminatory power, it represents a new class of circulating oncometabolite with potential value for predicting NSCLC. Furthermore, as elevation of succinate level in LLC tumor model is accompanied by increased TAMs in the subcutaneous tumors and enhanced cancer metastasis, serum succinate may be a useful therapeutic biomarker for NSCLC treatment. The present invention also provides an anti-succinate antibody that can serve as a cancer therapeutic agent.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

A sub-nanometer gold sticker for blocking efficiently endotoxin activity to protect against sepsis is disclosed. The sub-nanometer gold sticker comprises a gold nanocluster that serves as a flake-like substrate and a coating of short alkyl motifs that act as an adhesive, allowing the sub-nanometer gold sticker to dock with LPS by compacting the intramolecular hydrocarbon chain-chain distance (d-spacing) of lipid A, an endotoxicity active site that can cause overwhelming cytokine induction resulting in sepsis progression. Methods of blocking endotoxin activity, and suppressing pro-inflammatory cytokines are also disclosed. Also disclosed is a method of protecting against endotoxin-induced sepsis via increasing critical micelle concentration for the inhibition of LPS non-lamellar aggregation.

IPC Classes  ?

• A61K 33/242 - GoldCompounds thereof
• C09D 179/02 - Polyamines

Abstract

An isolated antibody, comprising heavy chain complementary determining regions CDR1, CDR2, and CDR3 from a heavy chain variable region sequence having SEQ ID NO: 1 or 3; light chain complementary determining regions CDR1, CDR2, and CDR3 from a light chain variable region sequence having SEQ ID NO: 2 or 4; wherein the antibody binds specifically to both vascular endothelial growth factor receptor-2 (VEGFR2) and vascular endothelial growth factor receptor-3 (VEGFR3).

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Disclosed is an adapted Madin-Darby canine kidney cell line capable of suspension culture in the absence of serum, and a chemically-defined medium for culture of the adapted MDCK cell line. Further disclosed are culture methods for growing the adapted MDCK cell line and methods for producing a vaccine from the adapted MDCK cell line grown in the chemically-defined medium.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/12 - Viral antigens
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

A focused ultrasound device and method for dermatological treatment. The focused ultrasound device includes a focused ultrasound applicator, an automatic motion mechanism, a driver, a computer, a software operation interface. In addition, the focused ultrasound method for dermatological treatment utilizes the same focused ultrasound applicator, to achieve coaxial deep layer and shallow layer ablation treatment of the skin.

IPC Classes  ?

• A61N 7/02 - Localised ultrasound hyperthermia

Abstract

The present invention provides novel substituted benzimidazole derivatives of formula (I) used as DAAO inhibitors and for treatment and/or prevention of neurological disorders.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia

Abstract

The present invention discloses an therapeutic ultrasonic device consisting of at least one arc ultrasonic transducer that can be assembled. The arc ultrasonic transducer comprises a protruding part, a concave part and a plurality of piezoelectric vibrating parts. The protruding part and the concave part are disposed at two ends of the arc ultrasonic transducer respectively, and the piezoelectric vibrating parts are disposed at the inner arc face of the arc ultrasonic transducer. Various numbers of arc ultrasonic transducers can be used in assembled structure or non-assembled structure according to different body size and focal zones of various target tissue. Thus the therapeutic ultrasonic device of the present invention is widely used in treatment of various indications.

IPC Classes  ?

• A61N 7/02 - Localised ultrasound hyperthermia
• A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• A61B 17/00 - Surgical instruments, devices or methods
• A61N 7/00 - Ultrasound therapy

Abstract

Heterocyclic compounds of formula I shown below and pharmaceutical compositions containing one of such compounds: Also disclosed is a method of treating a condition modulated by the colony-stimulating factor-1 receptor with one of the heterocyclic compounds.

IPC Classes  ?

• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07D 239/88 - Oxygen atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

Heterocyclic compounds of formula I shown below and pharmaceutical compositions containing one of such compounds: Also disclosed is a method of treating a condition modulated by the colony-stimulating factor-1 receptor with one of the heterocyclic compounds.

IPC Classes  ?

• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 35/00 - Antineoplastic agents

Abstract

Provided herein are compounds of Formula (I). The compounds described herein are useful in treating a disease associated with the expression of endogenous embryonic/fetal globin (e.g., γ globin) in erythrocytes (e.g., treating β -thalassemia and/or sickle cell disease through at least the induction of the globin gene expression in erythrocytes), and/or anemia (β-thalassemia and/or sickle cell anemia). The compounds described herein are useful in treating, delaying, and/or preventing the adverse effects of β-thalassemia and/or sickle cell disease, inducing γ globin production, and/or inducing the expression of embryonic/fetal globin genes in a subject, cell, tissue, or biological sample. Also provided in the present disclosure are pharmaceutical compositions, kits, and methods of using the compounds for inducing γ globin production described herein and for treating any of the target diseases described herein.

IPC Classes  ?

• C07D 473/16 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
• C07D 473/18 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 7/06 - Antianaemics

Abstract

The present invention relates to a three-dimensional (3D) tissue-like implant for transplanting to a subject in need comprising a cell cluster comprising mesenchymal stem cells (MSCs) and specific cells differentiated therefrom. The present invention also relate to a method of preparing a 3D-tissue-like implant from MSCs, particularly by seeding MSCs in alginate scaffolds and culturing the alginate scaffolds with MSCs in a 3-D perfusion condition. Further, the present invention provides a method for treating a defect in a recipient patient in need by administering a 3D tissue-like implant as described herein to the patient at a defective site e.g. a bone defective site.

IPC Classes  ?

• A61L 27/38 - Animal cells
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

Abstract

The present invention discloses a mosquito trap for capturing two or more types of mosquitoes into different chambers. The mosquito trap comprises a mosquito recognition system and a capturing mechanism. The mosquito recognition system captures image information of a mosquito and recognizes the type of the mosquito, and the capturing mechanism captures mosquitoes to different chambers with respect to the decision of the mosquito recognition system. With the present invention, live mosquitoes can be captured and differentiated to different types; additionally, the environmental values can also be recorded for further research.

IPC Classes  ?

• A01M 1/06 - Stationary means for catching or killing insects using a suction effect